QRD Pharma

Executive Summary

QRD Pharma is a privately held, GLP-compliant bioanalysis contract research organization (CRO) headquartered in New York. Founded in 2015, the company specializes in high-quality LC-MS services for drug discovery and development, with additional expertise in chiral analysis using supercritical fluid chromatography. QRD is currently expanding its service offerings to include in vitro DMPK (drug metabolism and pharmacokinetics) support, aiming to provide comprehensive preclinical solutions. As a science-centric lab, QRD serves pharmaceutical and biotechnology clients seeking reliable, outsourced bioanalytical services. The company's growth strategy focuses on broadening its analytical capabilities, maintaining regulatory compliance, and forming strategic partnerships to capture a larger share of the CRO market. With no disclosed funding or valuation, QRD operates as a lean service provider in a competitive landscape.

Upcoming Catalysts (preview)

• Q2 2026Launch of in vitro DMPK service line70% success
• Q3 2026Strategic partnership with a top-20 pharma company50% success
• Q4 2026GLP compliance audit pass or new accreditation (e.g., ISO 17025)80% success